Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors-Reference-Cited by-同舟云学术

Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors

Published:2023-09-29 Issue:19 Volume:66 Page:13384-13399
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Taylor Alexander M.¹^ORCID,Williams Bret R.¹,Giordanetto Fabrizio²^ORCID,Kelley Elizabeth H.¹,Lescarbeau André¹,Shortsleeves Kelley¹,Tang Yong¹,Walters W. Patrick¹^ORCID,Arrazate Alfonso³,Bowman Christine³,Brophy Erin¹,Chan Emily W.³,Deshmukh Gauri³,Greisman Jack B.²^ORCID,Hunsaker Thomas L.³,Kipp D. Randal¹^ORCID,Saenz Lopez-Larrocha Pablo³,Maddalo Danilo³,Martin Iain J.¹,Maragakis Paul²,Merchant Mark³,Murcko Mark¹,Nisonoff Hunter²^ORCID,Nguyen Vi¹,Nguyen Vy¹,Orozco Olivia¹,Owen Christopher¹,Pierce Levi¹,Schmidt Molly¹^ORCID,Shaw David E.²⁴^ORCID,Smith Sherri¹,Therrien Eric⁵^ORCID,Tran John C.³,Watters Jim¹,Waters Nigel J.¹,Wilbur Jeremy¹,Willmore Lindsay²

Affiliation:

1. Relay Therapeutics, Inc., 399 Binney St., Cambridge,, Massachusetts 02139, United States

2. D. E. Shaw Research, 120 W. 45th St., 39th Fl., New York, New York 10036, United States

3. Genentech, Inc., 1 DNA Way Mailstop 258A, South San Francisco, California 94080-4990, United States

4. Department of Biochemistry and Molecular Biophysics, Columbia University, 701 West 168th St., New York, New York 10032, United States

5. Schrödinger, Inc., 1540 Broadway, 24th Floor, New York, New York 10036, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00483

Reference35 articles.

1. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

2. A comprehensive review of SHP2 and its role in cancer

3. The biological function of SHP2 in human disease

4. SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment

5. Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers;Cancer Letters;2024-02

2. Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure–activity–relationship, and sleep-promoting properties in rats;RSC Medicinal Chemistry;2024

3. Targeting phosphatases: From molecule design to clinical trials;European Journal of Medicinal Chemistry;2024-01

4. Discovery of SHP2 Inhibitor GDC-1971 (RLY-1971) Containing a Pyrazolopyrazine Core;Synfacts;2023-12-08

5. Discovery of 5-Azaquinoxaline Derivatives as Potent and Orally Bioavailable Allosteric SHP2 Inhibitors;ACS Medicinal Chemistry Letters;2023-11-15